Ischaemiás szívbetegek szúróvizsgálati koleszterin adatai a Scandinavian Simvastatin Survival Study tükrében.

Translated title of the contribution: Data on cholesterol level screening of patients with ischemic heart disease in the light of the Scandinavian Simvastatin Survival Study

L. Márk, A. Kondacs, V. Hanyecz, G. Simondán

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The authors carried out a coronary heart disease risk factor screening on 1240 people of two villages of Békés county, Hungary. The prevalence of coronary heart disease among the 969 people 35-70 years old was 12.0%, in the different age groups varied between 0.8 and 20.9%. This high prevalence could be explained by the high occurence of the different risk factors. The results of cholesterol levels were analysed according to that of Scandinavian Simvastatin Survival Study. From 35-70 years old screened people with coronary heart disease 77 had a cholesterol level between 5.5 and 8.0 mmol/l. In these patients with 20-40 mg daily dose of simvastatin during 5.4 years long treatment from 7 predicted coronary death 3, from 17 expected non fatal myocardial infarction 5, from 13 anticipated revascularisation procedures 5 would be preventable. The 5.4 years long treatment with 20 mg simvastatin calculated with the prices of July 1996 in Hungary would cost 292831 forints, from which 87847 has to be paid by the patient. If the decrease of hospitalization costs of the coronary heart disease patients treated with simvastatin is also taken into account, the drug treatment costs, according to the literature, could be reduced with additional 88%.

Original languageHungarian
Pages (from-to)1679-1682
Number of pages4
JournalOrvosi Hetilap
Volume138
Issue number26
Publication statusPublished - Jun 29 1997

Fingerprint

Simvastatin
Myocardial Ischemia
Coronary Disease
Cholesterol
Survival
Hungary
Costs and Cost Analysis
Drug Costs
Health Care Costs
Hospitalization
Age Groups
Myocardial Infarction
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ischaemiás szívbetegek szúróvizsgálati koleszterin adatai a Scandinavian Simvastatin Survival Study tükrében. / Márk, L.; Kondacs, A.; Hanyecz, V.; Simondán, G.

In: Orvosi Hetilap, Vol. 138, No. 26, 29.06.1997, p. 1679-1682.

Research output: Contribution to journalArticle

@article{fd107953d4074fc2998989deecd1dc08,
title = "Ischaemi{\'a}s sz{\'i}vbetegek sz{\'u}r{\'o}vizsg{\'a}lati koleszterin adatai a Scandinavian Simvastatin Survival Study t{\"u}kr{\'e}ben.",
abstract = "The authors carried out a coronary heart disease risk factor screening on 1240 people of two villages of B{\'e}k{\'e}s county, Hungary. The prevalence of coronary heart disease among the 969 people 35-70 years old was 12.0{\%}, in the different age groups varied between 0.8 and 20.9{\%}. This high prevalence could be explained by the high occurence of the different risk factors. The results of cholesterol levels were analysed according to that of Scandinavian Simvastatin Survival Study. From 35-70 years old screened people with coronary heart disease 77 had a cholesterol level between 5.5 and 8.0 mmol/l. In these patients with 20-40 mg daily dose of simvastatin during 5.4 years long treatment from 7 predicted coronary death 3, from 17 expected non fatal myocardial infarction 5, from 13 anticipated revascularisation procedures 5 would be preventable. The 5.4 years long treatment with 20 mg simvastatin calculated with the prices of July 1996 in Hungary would cost 292831 forints, from which 87847 has to be paid by the patient. If the decrease of hospitalization costs of the coronary heart disease patients treated with simvastatin is also taken into account, the drug treatment costs, according to the literature, could be reduced with additional 88{\%}.",
author = "L. M{\'a}rk and A. Kondacs and V. Hanyecz and G. Simond{\'a}n",
year = "1997",
month = "6",
day = "29",
language = "Hungarian",
volume = "138",
pages = "1679--1682",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "26",

}

TY - JOUR

T1 - Ischaemiás szívbetegek szúróvizsgálati koleszterin adatai a Scandinavian Simvastatin Survival Study tükrében.

AU - Márk, L.

AU - Kondacs, A.

AU - Hanyecz, V.

AU - Simondán, G.

PY - 1997/6/29

Y1 - 1997/6/29

N2 - The authors carried out a coronary heart disease risk factor screening on 1240 people of two villages of Békés county, Hungary. The prevalence of coronary heart disease among the 969 people 35-70 years old was 12.0%, in the different age groups varied between 0.8 and 20.9%. This high prevalence could be explained by the high occurence of the different risk factors. The results of cholesterol levels were analysed according to that of Scandinavian Simvastatin Survival Study. From 35-70 years old screened people with coronary heart disease 77 had a cholesterol level between 5.5 and 8.0 mmol/l. In these patients with 20-40 mg daily dose of simvastatin during 5.4 years long treatment from 7 predicted coronary death 3, from 17 expected non fatal myocardial infarction 5, from 13 anticipated revascularisation procedures 5 would be preventable. The 5.4 years long treatment with 20 mg simvastatin calculated with the prices of July 1996 in Hungary would cost 292831 forints, from which 87847 has to be paid by the patient. If the decrease of hospitalization costs of the coronary heart disease patients treated with simvastatin is also taken into account, the drug treatment costs, according to the literature, could be reduced with additional 88%.

AB - The authors carried out a coronary heart disease risk factor screening on 1240 people of two villages of Békés county, Hungary. The prevalence of coronary heart disease among the 969 people 35-70 years old was 12.0%, in the different age groups varied between 0.8 and 20.9%. This high prevalence could be explained by the high occurence of the different risk factors. The results of cholesterol levels were analysed according to that of Scandinavian Simvastatin Survival Study. From 35-70 years old screened people with coronary heart disease 77 had a cholesterol level between 5.5 and 8.0 mmol/l. In these patients with 20-40 mg daily dose of simvastatin during 5.4 years long treatment from 7 predicted coronary death 3, from 17 expected non fatal myocardial infarction 5, from 13 anticipated revascularisation procedures 5 would be preventable. The 5.4 years long treatment with 20 mg simvastatin calculated with the prices of July 1996 in Hungary would cost 292831 forints, from which 87847 has to be paid by the patient. If the decrease of hospitalization costs of the coronary heart disease patients treated with simvastatin is also taken into account, the drug treatment costs, according to the literature, could be reduced with additional 88%.

UR - http://www.scopus.com/inward/record.url?scp=0031590019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031590019&partnerID=8YFLogxK

M3 - Article

C2 - 9289681

AN - SCOPUS:0031590019

VL - 138

SP - 1679

EP - 1682

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 26

ER -